Consistent with this, both mutations frequently co-occur with ATRX inactivation in gliomas, and both H3.3 G34R and IDH1 R132H have been shown to promote ALT when combined with inactivation of ATRX/TP53 and telomerase (70). This evidence concerns the gene IDH1 and central nervous system cancer.